Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.7005 -0.0395 (-5.34%)
Streaming Delayed Price Updated: 10:10 AM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate in Upcoming Investor Events
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Presentation at the World Vaccine Congress Washington
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
From Invivyd
Via GlobeNewswire
News headline image
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.